

# ForPatients

by Roche

Juvenile Idiopathic Arthritis

## A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

**Trial Status**  
Completed

**Trial Runs In**  
12 Countries

**Trial Identifier**  
NCT01904292 2012-003490-26  
WA28118

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This open-label, multicenter study will evaluate the pharmacokinetics, pharmacodynamics, and safety of subcutaneously administered tocilizumab in participants with Systemic Juvenile Idiopathic Arthritis (sJIA). Participants with body weight less than (<) 30 kilograms (kg) will receive subcutaneous (SC) tocilizumab dose every 2 weeks (Q2W) and participants with body weight greater than or equal to ( $\geq$ ) 30 kg will receive weekly (QW), for 52 weeks. Tocilizumab was administered every 10 days until pre-planned interim analysis was performed and changed to Q2W in participants with body weight <30 kg.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT01904292 2012-003490-26 WA28118**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
 $\geq 1$  Year &  $\leq 17$  Years

**Healthy Volunteers**  
No

---